Publications by authors named "Reiner Meyer"
Article Synopsis
- KRAS is a key oncogenic driver in cancers and relies on protein-protein interactions (PPIs) for its signaling, especially with SOS1 for activation.
- A study found that adding just one atom between specific residues in SOS1 can turn the SOS1 activators into inhibitors.
- This new method, which utilizes small modifications rather than large molecules, shows promise in inhibiting challenging PPIs like SOS1-KRAS, especially when combined with the EGFR inhibitor afatinib to target KRAS mutant colorectal tumors.
Clinical studies of pharmacologic agents targeting the insulin-like growth factor (IGF) pathway in unselected cancer patients have so far demonstrated modest efficacy outcomes, with objective responses being rare. As such, the identification of selection biomarkers for enrichment of potential responders represents a high priority for future trials of these agents. Several reports have described high IGF2 expression in a subset of colorectal cancers, with focal amplification being responsible for some of these cases.
View Article and Find Full Text PDF